Suptavumab

Suptavumab (REGN2222) is a human monoclonal antibody. Suptavumab can bind and block a conserved epitope on RSV A and B subtypes. Suptavumab can be used for the research of RSV infection[1][2].

Product Specifications

CAS Number

[1629615-23-1]

Product Name Alternative

REGN2222

UNSPSC

12352203

Target

RSV

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/suptavumab.html

Purity

95.0

Solubility

10 mM in DMSO

Smiles

[Suptavumab]

Molecular Weight

(145.8 kDa)

References & Citations

[1]Simões EAF, et al. Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants. Clin Infect Dis. 2021 Dec 6;73 (11) :e4400-e4408. |[2]Rodriguez-Fernandez R, et al. Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Infection. Pediatr Infect Dis J. 2021 May 1;40 (5S) :S35-S39.